Sarepta Therapeutics, Inc. (SRPT)
18.13
-0.66
(-3.51%)
USD |
NASDAQ |
Aug 24, 16:00
18.13
0.00 (0.00%)
After-Hours: 19:54
Sarepta Therapeutics Debt to Equity Ratio : 0.6845 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.6845 |
| March 31, 2026 | 0.6888 |
| December 31, 2025 | 0.9114 |
| September 30, 2025 | 0.947 |
| June 30, 2025 | 0.9974 |
| March 31, 2025 | 1.176 |
| December 31, 2024 | 0.879 |
| September 30, 2024 | 1.144 |
| June 30, 2024 | 1.272 |
| March 31, 2024 | 1.435 |
| December 31, 2023 | 1.625 |
| September 30, 2023 | 1.794 |
| June 30, 2023 | 1.841 |
| March 31, 2023 | 1.807 |
| December 31, 2022 | 4.202 |
| September 30, 2022 | 3.663 |
| June 30, 2022 | 1.570 |
| March 31, 2022 | 1.327 |
| December 31, 2021 | 1.243 |
| September 30, 2021 | 2.467 |
| June 30, 2021 | 2.388 |
| March 31, 2021 | 2.151 |
| December 31, 2020 | 1.436 |
| September 30, 2020 | 0.8617 |
| June 30, 2020 | 0.735 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.6579 |
| December 31, 2019 | 0.9013 |
| September 30, 2019 | 0.4961 |
| June 30, 2019 | 0.4443 |
| March 31, 2019 | 0.3544 |
| December 31, 2018 | 0.4074 |
| September 30, 2018 | 0.6493 |
| June 30, 2018 | 0.6286 |
| March 31, 2018 | 0.5546 |
| December 31, 2017 | 0.5462 |
| September 30, 2017 | 0.0449 |
| June 30, 2017 | 0.0297 |
| March 31, 2017 | 0.0319 |
| December 31, 2016 | 0.048 |
| September 30, 2016 | 0.0455 |
| June 30, 2016 | 0.1664 |
| March 31, 2016 | 0.151 |
| December 31, 2015 | 0.1229 |
| September 30, 2015 | 0.189 |
| June 30, 2015 | 0.1552 |
| March 31, 2015 | 0.0318 |
| December 31, 2014 | 0.0256 |
| September 30, 2014 | 0.0219 |
| June 30, 2014 | 0.0054 |
| March 31, 2014 | 0.0072 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Moderna, Inc. | 0.1904 |
| ImmunityBio, Inc. | -1.174 |
| X4 Pharmaceuticals, Inc. | 0.4968 |
| MapLight Therapeutics, Inc. | 0.0057 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 3.189B |
| Total Liabilities (Quarterly) | 1.661B |
| Shareholders Equity (Quarterly) | 1.528B |
| Current Ratio | 4.422 |
| Net Debt Paydown Yield | 3.14% |